Equities analysts expect that Kindred Biosciences Inc (NASDAQ:KIN) will post earnings of ($0.37) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.36). Kindred Biosciences reported earnings of ($0.39) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 5.1%. The firm is expected to report its next earnings results on Thursday, August 8th.
On average, analysts expect that Kindred Biosciences will report full year earnings of ($1.45) per share for the current fiscal year, with EPS estimates ranging from ($1.60) to ($1.24). For the next financial year, analysts expect that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.21) to ($0.83). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Kindred Biosciences.
Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $1.95 million.
A number of analysts have weighed in on KIN shares. Lake Street Capital decreased their target price on shares of Kindred Biosciences from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 7th. Cantor Fitzgerald set a $25.00 price target on Kindred Biosciences and gave the stock a “buy” rating in a research note on Friday, April 26th. Zacks Investment Research lowered Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Kindred Biosciences in a research note on Thursday, March 7th. Finally, BidaskClub lowered Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $17.11.
NASDAQ KIN traded down $0.26 during trading hours on Friday, reaching $8.41. The company’s stock had a trading volume of 3,618 shares, compared to its average volume of 178,237. The firm has a market cap of $351.05 million, a PE ratio of -5.23 and a beta of 0.37. Kindred Biosciences has a 52 week low of $8.04 and a 52 week high of $15.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.10 and a quick ratio of 8.70.
A number of hedge funds and other institutional investors have recently modified their holdings of KIN. Bank of New York Mellon Corp raised its position in Kindred Biosciences by 24.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 90,847 shares of the biopharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 17,798 shares in the last quarter. BlackRock Inc. raised its position in Kindred Biosciences by 38.1% during the 3rd quarter. BlackRock Inc. now owns 1,829,393 shares of the biopharmaceutical company’s stock valued at $25,520,000 after purchasing an additional 504,246 shares in the last quarter. Man Group plc bought a new stake in Kindred Biosciences during the 3rd quarter valued at $942,000. MetLife Investment Advisors LLC raised its position in Kindred Biosciences by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 21,274 shares of the biopharmaceutical company’s stock valued at $297,000 after purchasing an additional 7,563 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in Kindred Biosciences by 28.6% during the 3rd quarter. Teachers Advisors LLC now owns 57,607 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 12,810 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Recommended Story: Forex
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.